MARKET NEWS

Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes
Avacta Announces AffiDX SARS-CoV-2 Antigen Lateral Flow Test Detects Delta Variant
CN Bio’s PhysioMimix Adopted by King’s College London to Investigate Chronic Liver Disease
Orchard Therapeutics Announces Regulatory & Clinical Updates for Lead Gene Therapy Programs
CicloMed Announces Initiation of Phase 1B Trial of Fosciclopirox in Newly Diagnosed & Recurrent Urothelial Cancer Patients
Addex Therapeutics Initiates Pivotal Phase 2b/3 Study With Dipraglurant for Dyskinesia Associated With Parkinson’s Disease

  FEATURED EDITORIAL

  COMPANY PROFILE

Pace Analytical Life Sciences (PLS) is a premier contract development & manufacturing (CDMO) and contract research (CRO) organization helping to improve human health by supporting the Pharmaceutical, Biologics, and Gene Therapy innovators. We help to bring new therapies to market starting with early-phase drug development through successful clinical outcomes and on through commercialization and late-phase manufacturing. We share a common goal to bring real value to people, healthcare professionals and health businesses around the world. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Evonik Markets Novel Chemical Technology for More Sustainable Pharmaceutical Production

Evonik Markets Novel Chemical Technology for More Sustainable Pharmaceutical Production

Evonik offers an innovative green technology that enables the large-scale synthesis of active pharmaceutical ingredients in water. The “Chemistry in Water” technology has the potential….

LEXEO Therapeutics Receives Rare Pediatric Disease Designation & Orphan Drug Designation 

LEXEO Therapeutics Receives Rare Pediatric Disease Designation & Orphan Drug Designation 

LEXEO Therapeutics recently announced the US FDA has granted Rare Pediatric Disease designation and Orphan Drug designation to LX2006 for the treatment of….

InMed Pharmaceuticals Signs Non-Binding Letter of Intent to Acquire BayMedica, a Commercial Manufacturer of Rare Cannabinoids

InMed Pharmaceuticals Signs Non-Binding Letter of Intent to Acquire BayMedica, a Commercial Manufacturer of Rare Cannabinoids

InMed Pharmaceuticals Inc. recently announced it has entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of….

eTheRNA immunotherapies & Quantoom Biosciences Announce Strategic Collaboration for the Development of a Novel RNA Production

eTheRNA immunotherapies & Quantoom Biosciences Announce Strategic Collaboration for the Development of a Novel RNA Production

eTheRNA immunotherapies NV and Quantoom Biosciences S.A. recently announced they are to collaborate on the development of a revolutionary RNA production system (RPS) for both research and GMP-grade material…..

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

July 28 – Excipients
August 4 – Controlled Release